Viewing Study NCT00996957


Ignite Creation Date: 2025-12-24 @ 6:47 PM
Ignite Modification Date: 2025-12-31 @ 9:04 AM
Study NCT ID: NCT00996957
Status: COMPLETED
Last Update Posted: 2013-03-18
First Post: 2009-10-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma
Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module